Guanfacine Extended Release ( DrugBank: Guanfacine )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
193プラダー・ウィリ症候群2

193. プラダー・ウィリ症候群


臨床試験数 : 113 薬物数 : 111 - (DrugBank : 26) / 標的遺伝子数 : 48 - 標的パスウェイ数 : 102
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05657860
(ClinicalTrials.gov)
December 17, 202012/12/2022Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi SyndromeA Double Blind, Placebo Controlled, Fixed-Flexible Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi SyndromePrader-Willi Syndrome;Aggression;Self-Injurious Behavior;Pathologic Processes;Behavioral Symptoms;Intellectual Disability;Neurobehavioral Manifestations;Neurologic Manifestations;Nervous System Diseases;Abnormalities, Multiple;Congenital Abnormalities;Chromosome Disorders;Genetic Diseases, Inborn;Obesity;Overnutrition;Nutrition Disorders;Antihypertensive Agents;Neurotransmitter Agents;Molecular Mechanisms of Pharmacological Action;Physiological Effects of Drugs;Skin-PickingDrug: Guanfacine Extended Release;Other: PlaceboMaimonides Medical CenterNULLRecruiting6 Years35 YearsAll33Phase 4United States
2NCT04066088
(ClinicalTrials.gov)
December 1, 201921/8/2019Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi SyndromeDose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi SyndromePrader-Willi SyndromeOther: Placebo;Drug: Guanfacine extended release (GXR)NYU Langone HealthWinthrop University HospitalWithdrawn6 Years35 YearsAll0Phase 4United States